Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4685 Target Snapshot

Indoleamine 2,3-dioxygenase 1 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
5,262Compounds
799Assays
10Approved Drugs
7,580.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Indoleamine 2,3-dioxygenase 1 shows late clinical disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P14902. Start with cancer, then reuse UniProt P14902 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with cancer, then reuse UniProt P14902 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 2 linked drugs
Open source guide
Disease program
cancer

Indoleamine 2,3-dioxygenase 1 shows late clinical disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with cancer because it currently carries late clinical support. Linked drugs include EPACADOSTAT, LINRODOSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Indoleamine 2,3-dioxygenase 1 as ChEMBL target CHEMBL4685, mapped to UniProt P14902. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Indoleamine 2,3-dioxygenase 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4685
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P14902
Indoleamine 2,3-dioxygenase 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Indoleamine 2,3-dioxygenase 1 is the right protein anchor across sources, using UniProt P14902 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why cancer is currently framed as late clinical support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameIndoleamine 2,3-dioxygenase 1
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP14902
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelIndoleamine 2,3-dioxygenase 1
UniProt AccessionP14902
Component TypeProtein
Sequence Length403 aa

Indoleamine 2,3-dioxygenase 1

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Indoleamine 2,3-dioxygenase 1, mapped to UniProt P14902. Sequence length is 403 aa.

Mapped IDP14902
Review nameIndoleamine 2,3-dioxygenase 1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

Indoleamine 2,3-dioxygenase 1 shows late clinical disease relevance led by cancer. 5 more disease programs remain visible in the same review block.

Late clinical Phase III
cancer
2 linked drugs · 2 direct · 2 efficacy
Linked drugEPACADOSTAT
Linked drugLINRODOSTAT
Late clinical Phase III
head and neck malignant neoplasia
2 linked drugs · 2 direct · 2 efficacy
Linked drugEPACADOSTAT
Linked drugLINRODOSTAT
Late clinical Phase III
lung cancer
2 linked drugs · 2 direct · 2 efficacy
Linked drugEPACADOSTAT
Linked drugLINRODOSTAT
Late clinical Phase III
melanoma
2 linked drugs · 2 direct · 2 efficacy
Linked drugEPACADOSTAT
Linked drugLINRODOSTAT
Late clinical Phase III
neoplasm
2 linked drugs · 2 direct · 2 efficacy
Linked drugEPACADOSTAT
Linked drugLINRODOSTAT
Late clinical Phase III
non-small cell lung carcinoma
2 linked drugs · 2 direct · 2 efficacy
Linked drugEPACADOSTAT
Linked drugLINRODOSTAT
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with cancer because it currently carries late clinical support. Linked drugs include EPACADOSTAT, LINRODOSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasecancer
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

10
Approved
6
Phase III
10
Phase II
3
Phase I
Assay Mix

Activity Type Distribution

IC506,923.0
KI224.0
EC50360.0
KD73.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL432537 10.74 IC50 0.018 Preclinical
CHEMBL5207194 10.1 IC50 0.08 Preclinical
CHEMBL4645108 10.05 IC50 0.09 Preclinical
CHEMBL4863767 10.0 IC50 0.1 Preclinical
CHEMBL5192384 9.96 Ki 0.11 Preclinical
CHEMBL4086143 9.92 IC50 0.12 Preclinical
CHEMBL4855797 9.89 IC50 0.13 Preclinical
CHEMBL5192977 9.82 Ki 0.15 Preclinical
CHEMBL5192977 9.8 Kd 0.158 Preclinical
CHEMBL4848630 9.54 IC50 0.29 Preclinical
Distribution

pChEMBL Value Distribution

545
5.0
569
5.5
791
6.0
869
6.5
1001
7.0
439
7.5
271
8.0
129
8.5
44
9.0
7
9.5
pChEMBL
Approved Drugs

Approved Drugs

MENADIONE
CHEMBL590
Approved 1982
Properties Compare Identifier
BERBERINE
CHEMBL295124
Properties Compare Identifier
Assay Landscape

Assay Landscape

799
Total Assays
4,532
Tested Compounds
2
Assay Types
Binding — 796 assays, 4,532 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 308 1,502 6.0
assay format 230 1,539 6.5
cell-based format 208 1,240 6.7
tissue-based format 50 251 7.2
ADME — 3 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 0 —
assay format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine